Cardiovascular complications in COVID-19

Brit Long, William J Brady, Alex Koyfman, Michael Gottlieb, Brit Long, William J Brady, Alex Koyfman, Michael Gottlieb

Abstract

Background: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur.

Objective: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection.

Discussion: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications.

Conclusions: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.

Keywords: Acute myocardial infarction; COVID-19; Cardiovascular; Dysrhythmia; Heart failure; Infectious disease; Myocarditis; Troponin.

Conflict of interest statement

Declaration of competing interest None.

Published by Elsevier Inc.

Figures

Fig. 1
Fig. 1
COVID-19 and the cardiovascular system.

References

    1. World Health Organization WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available online at.
    1. Coronavirus Disease 2019 (COVID-19) Centers for Disease Control and Prevention.
    1. World Health Organization Situation report.
    1. Driggin E., Madhavan M.V., Bikdeli B. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. Mar 18 2020 [pii: S0735-1097(20)34637-4, in press]
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Feb 24 2020 doi: 10.1001/jama.2020.2648. [Epub ahead of print]
    1. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020:1–3. doi: 10.1007/s00134-020-05991-x. [published online ahead of print, 2020 Mar 3]
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Mar 28 2020;395(10229):1054–1062.
    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. Feb 7 2020 doi: 10.1001/jama.2020.1585. [Epub ahead of print]
    1. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. Jun 2004;203(2):631–637.
    1. Zhou P., Yang X.L., Wang X.G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Mar 2020;579(7798):270–273.
    1. Ge X.Y., Li J.L., Yang X.L. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–538.
    1. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. Apr 2020;46(4):586–590.
    1. Libby P., Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718–1720.
    1. Kwong J.C., Schwartz K.L., Campitelli M.A. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378:345–353.
    1. Davis M.M., Taubert K., Benin A.L. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol. 2006;48:1498–1502.
    1. Chen L., Li X., Chen M., Feng Y., Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. Mar 30 2020 doi: 10.1093/cvr/cvaa078. [pii: cvaa078, Epub ahead of print]
    1. Li B., Yang J., Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. Mar 11 2020 doi: 10.1007/s00392-020-01626-9. [Epub ahead of print]
    1. Murthy S., Gomersall C.D., Fowler R.A. Care for critically ill patients with COVID-19. JAMA. Mar 11 2020 doi: 10.1001/jama.2020.3633. [Epub ahead of print]
    1. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Yang X., Yu Y., Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. Feb 24 2020 doi: 10.1016/S2213-2600(20)30079-5. [pii: S2213-2600(20)30079-5, Epub ahead of print]
    1. Weiss P., Murdoch D.R. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014–1015. doi: 10.1016/S0140-6736(20)30633-4.
    1. Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care. March 27, 2020. Accessed March 30, 2020.
    1. Alhogbani T. Acute myocarditis associated with novel middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36:78–80.
    1. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. Mar 2020 doi: 10.1007/s00059-020-04909-z. [Epub ahead of print]
    1. Liu K., Fang Y.Y., Deng Y. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) Feb 7 2020 doi: 10.1097/CM9.0000000000000744. [Epub ahead of print]
    1. Xu Z., Shi L., Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. Apr 2020;8(4):420–422.
    1. Liu Y., Yang Y., Zhang C. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–374.
    1. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. doi:10.1001/jamacardio.2020.0950.
    1. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. doi:10.1001/jamacardio.2020.1017.
    1. Corrales-Medina V.F., Alvarez K.N., Weissfeld L.A. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313:264–274.
    1. Welt F.G.P., Shah P.B., Aronow H.D., from the American College of Cardiology’s (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI) Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC’s Interventional Council and SCAI. JACC. 2020 doi: 10.1016/j.jacc.2020.03.021.
    1. Chen T., Wu D., Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. Mar 26 2020;368
    1. Buzon J., Roignot O., Lemoine S. Takotsubo cardiomyopathy triggered by influenza A virus. Intern Med. 2015;54:2017–2019.
    1. Xie Y., Wang X., Yang P., Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology: Cardiothoracic Imaging. 2020;2(2)
    1. Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. Mar 30 2020 doi: 10.1093/eurheartj/ehaa254. [pii: ehaa254, Epub ahead of print]
    1. Chen J, Wang X, Zhang S, et al. Findings of acute pulmonary embolism in COVID-19 patients. Lancet Infectious Disease. [Available at SSRN: or ].
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. Apr 2020;18(4):844–847.
    1. Tang N., Bai H., Chen X. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. Mar 27 2020 doi: 10.1111/jth.14817. [Epub ahead of print]
    1. Chavez S., Long B., Koyfman A., Liang S. Coronavirus disease (COVID-19): a primer for emergency physicians. American Journal of Emergency Medicine. March 24, 2020 doi: 10.1016/j.ajem.2020.03.036. Published online.
    1. Elfiky A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248
    1. Chu C.M., Cheng V.C., Hung I.F. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256.
    1. KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product insert. AbbVie Inc. (per FDA); North Chicago, IL: 2013.
    1. Page R.L., II, O’Bryant C.L., Cheng D. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–e69.
    1. Tonnesmann E., Kandolf R., Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol. 2013;35:434–442.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir